EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

ROS-Responsive Nanoplatforms for Targeted Tumor Immunomodulation: A Paradigm Shift in Precision Cancer Immunotherapy

Yuan-Yuan Fan, Hong Wu, Chuan Xu

Pharmaceutics · 05.07.2025 · 17 (7) · 886

DOI: 10.3390/pharmaceutics17070886 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 05.07.2025. Verfasst von Yuan-Yuan Fan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Project of Sichuan Province Natural Science Foundation, Major Project of Chongqing Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite remarkable advancements in cancer immunotherapy, its clinical efficacy remains constrained in solid tumors due to the immunosuppressive tumor microenvironment (TME). Reactive oxygen species (ROS), which exhibit dual regulatory roles in the TME by regulating immunogenic cell death (ICD) and reprogramming immune cell functionality, have emerged as a pivotal therapeutic target. Nano-enabled drug delivery systems present distinct advantages for TME modulation due to their structural versatility, tumor-specific targeting precision, and spatiotemporally controlled drug release. In particular, ROS-responsive nanoplatforms demonstrate multifaceted immunomodulatory potential by synergistically restoring ICD and remodeling immunosuppressive immune cell phenotypes within the TME. These platforms further amplify the therapeutic outcomes of conventional modalities including chemotherapy, radiotherapy, and photodynamic therapy (PDT) through ROS-mediated sensitization mechanisms. This review comprehensively examines recent breakthroughs in ROS-responsive nanosystems for antitumor immunotherapy, emphasizing their mechanistic interplay with TME components and clinical translation potential. Herein, we provide a framework for developing integrated therapeutic strategies to overcome the current limitations in cancer immunotherapy.

Schlagwörter

Stichwörter der Autor:innen

ROS-responsive drug deliveryantitumor therapyimmunogenic cell deathreactive oxygen speciestumor microenvironment

Autor:innen und Institutionen

  • Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.
  • Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.
  • Yu-Yue Pathology Scientific Research Center, 313 Gaoteng Avenue, Chongqing 400039, China.
  • Jinfeng Laboratory, Chongqing 400039, China.

Förderung

  • National Natural Science Foundation of China
  • Key Project of Sichuan Province Natural Science Foundation
  • Major Project of Chongqing Natural Science Foundation
  • Key Project of Sichuan Provincial Science Foundation
  • Key Project of the Natural Science Foundation of Chongqing

Zitieren

APA

Fan, Y. Y., Wu, H., & Xu, C. (2025). ROS-Responsive Nanoplatforms for Targeted Tumor Immunomodulation: A Paradigm Shift in Precision Cancer Immunotherapy. Pharmaceutics, 17(7), 886. https://doi.org/10.3390/pharmaceutics17070886

Vancouver

Fan YY, Wu H, Xu C. ROS-Responsive Nanoplatforms for Targeted Tumor Immunomodulation: A Paradigm Shift in Precision Cancer Immunotherapy. Pharmaceutics. 2025;17(7):886. doi:10.3390/pharmaceutics17070886

BibTeX
@article{Fan2025,
  author = {Fan, Yuan-Yuan and Wu, Hong and Xu, Chuan},
  title = {ROS-Responsive Nanoplatforms for Targeted Tumor Immunomodulation: A Paradigm Shift in Precision Cancer Immunotherapy},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {7},
  pages = {886},
  doi = {10.3390/pharmaceutics17070886}
}
Kostenlos starten →